Peg-interferon for Inactive Chronic Hepatitis B Carriers

Inclusion Criteria: * Treatment naïve * Documented HBsAg or HBV DNA positive for ≥ 6 months. * Documented HBeAg negative and anti-HBe positive * ALT ≤1xULN * quantitative HBsAg \<1,000 IU/ml * HBV DNA \<2x104 IU/mL at screening * Absence of cirrhosis documented by liver biopsy or transient elastography within 6 months (Fibroscan®; Fibrosis stage \>2 (score ≥ 10Kpa) will not be eligible for this study.) * Patient has agreed not to take any other investigational drug or systemic anti-viral, cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated. * Patient is able to give written consent prior to study start and to comply with the study requirements. * Women of childbearing age must have a negative urine (ß-HCG) pregnancy test taken within 14 days of starting therapy Exclusion Criteria: * Patients who are currently on treatment with nucleoside/nucleotide analogues or have been treated for Hepatitis B in the past * Presence of cirrhosis documented by liver biopsy or transient elastography (score ≥ 10kpa) * Active Co-infection with HIV antibody, HCV antibody or HDV antibody positivity. * Evidence of decompensated liver disease defined as a direct (conjugated) bilirubin \>1.2x upper limit of normal (ULN), prothrombin time (PT) \>1.5xULN , serum bilirubin \<35g/L, or prior history of clinical hepatic decompensation as illustrated by presence of (eg. ascites, encephalopathy, variceal haemorrhage) * Evidence of hepatocellular …